New combo therapy shows promise for tough lung cancer
NCT ID NCT03589547
First seen Apr 04, 2026 · Last updated May 03, 2026 · Updated 7 times
Summary
This study tested a combination of the immune-boosting drug durvalumab and a precise, high-dose radiation treatment called SBRT for people with stage III lung cancer. The goal was to see if adding SBRT after standard chemoradiation could improve disease control and be safe. Only 11 people took part, and the focus was on side effects and how long the cancer stayed under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
Conditions
Explore the condition pages connected to this study.